View
Page
"The past year has been a turbulent one for Hikma. A shortage-fuelled growth spurt and a resulting guidance upgrade had heralded the Jordanian company’s entry into the FTSE 100 in March 2015 (following the c.25% rally since the beginning of the year), making it only the fourth pharma constituent to become a component of this ‘blue-chip’ index. Fast forward a year, however, and multiple downgrades later, investor enthusiasm towards the company had waned, resulting in the stock being kicked out of the index in March 2016." AlphaValue's view on research tree...
Latest from the Community...
Latest from the Community...
Latest from the Community...